Dr. Moxley is retired Professor of Neurology and Pediatrics, Division of Medicine, at the University of Rochester in Rochester, New York and Director of the Wellstone Muscular Dystrophy Center. After graduating from Harvard and the University of Pennsylvania Medical School, he completed his internship in Pennsylvania and then a Heart Disease and Stroke Control Program at NASA Headquarters. His residency was in Neurology at Harvard Medical Center and his fellowship in Medicine at Johns Hopkins University. He completed a Postdoctoral NIH special fellowship in Endocrinology and Metabolism at Johns Hopkins. In addition to the directorship of the muscular dystrophy center, he is Associate Chairman of the Department of Neurology at Strong Memorial Hospital, and formerly Director of EMG/Nerve Conduction Laboratory at Strong Memorial Hospital. With support from the NIH he initiated the National Registry for DM and FSHD (facioscapulohumoral dystrophy, another form of muscular dystrophy), a tool investigators can use to incorporate affected DM family members into their research. He has published numerous articles on myotonic dystrophy in professional journals and serves on many advisory boards and committees. Dr. Moxley has carried out an investigation of Mexiletine, a medication that relaxes myotonia, or muscle stiffness; and is currently conducting a clinical trial of SomatoKine in individuals with myotonic dystrophy.
Inhaltsverzeichnis
